cyrilzakka/clinical-trials huggingface dataset:
Concentration of S-1 Metabolites in Tear and Plasma of Patients Receiving TS-1

S-1 has been also shown to be an effective drug for palliative chemotherapy in Eastern and Western GC patients. Recently, some case and small-sized studies have been reported on lacrimal drainage obstruction(LDO)caused by S-1.Suggested mechanism of LDO involves direct secretion of S-1 into the tear; thus the concentration of S-1 metabolite in tear is expected to be high in patients who developed LDO than in patients without LDO. We investigate the concentration of S-1 and its metabolites in tear and plasma and find out its correlation with side effects such as LDO. These results will also help us identify patients who are at high risk of developing S-1-associated side effects.

1. S-1 metabolites concentration in plasma

   1. factors affecting plasma concentration

      * surgery subtype
      * serum creatinine
   2. systemic adverse effects of S-1 and its correlation with plasma S-1 metabolites concentration

      * enteritis
      * fatigue
2. S-1 metabolites concentration in tears

   1. correlation of tear concentration with plasma concentration
   2. lacrimal drainage obstruction caused by S-1 administration, and its correlation with tear S-1 metabolites concentration
   3. lacrimal drainage obstruction caused by S-1 administration, and its correlation with plasma S-1 metabolites concentration

Eligibility Criteria:
Inclusion Criteria:

* Patients who received radical surgery for gastric cancer
* Patients who receiving S-1 adjuvant chemotherapy
* Patients who administrated S-1 for more than 7 days

Exclusion Criteria:

* who using eyedrop medication
* who has dry eye that tear cannot be sampled
Hemodynamic Changes of Tracheal Intubation With McCoy and Macintosh Laryngoscopes

A total of 272 patients were randomly allocated into two groups, Patients in group A were treated with Macintosh laryngoscope and in groups B with McCoy laryngoscope was used for endotracheal intubation. Pulse and systolic blood pressure was recorded by non-invasive measures before laryngoscopy and at 30 seconds, 2 and 3minutes after intubation. All this information was recorded on a Pro forma.

After taking approval from hospital ethical committee, 272 patients who reported to Operation Theatre of CMH, Jhelum were selected for the study. Informed consent was obtained and patient demographic information (name, age, contact) was recorded. Patients were randomly divided in two equal groups by using lottery method. GROUP A: Where Macintosh laryngoscope was used for endotracheal intubation. GROUP B: Where McCoy laryngoscope was used for endotracheal intubation.

Before reporting to Operation theatre a detailed pre anesthesia assessment was done in all patients, all necessary laboratory investigations were collected. On OT table pulse and systolic blood pressure was checked by non-invasive method. 18G cannula was passed and ECG was attached. A pillow was placed under the head to obtain classical sniffing position for intubation. All the patients were pre medicated with injection midazolam 0.08mg/kg, injection nalbuphine 0.1 mg/kg, injection dexamethasone 0.08mg/kg and injection metoclopramide 0.1 mg/kg. Pre oxygenation was done with 100% oxygen for 3 mins. Induction was done with injection propofol2 mg/kg, muscle relaxation achieved with injection atracurium 0.5mg/kg. Laryngoscopy was started after 3 minutes by a qualified anesthetist. Pulse and systolic blood pressure was recorded by non-invasive measures before laryngoscopy and at 30 seconds, 2 and 3minutes after intubation. All this information was recorded on a Proforma.

Eligibility Criteria:
Inclusion Criteria:

* Both Male and Female
* Age between 18 to 70
* ASA I and II males and females.
* Malampatti I and II.
* Hemodynamically stable, no known ischemic heart disease and no history of hypertension.
* Nil per oral for at least 6 hours.

Exclusion Criteria:

* Non consenting patient.
* ASA III, IV or V patient.
* Malampati III or IV.
* Cervical instability
* Thyromental distance of less than 6cm, inter incisor distance of less than 3cm.
* Known case of hypertension and ischemic heart disease.
* Pregnant female.
* Body mass index of more than 30.
* Patients of oropharyngeal surgery.
* Unable to Intubate in less than 1 minute.
The Effect of Real-time Binaural Sound on Sedation Using Dexmedetomidine

The aim of the study is to evaluate whether real-time binaural sound affects the dose of dexmedetomidine in patients undergoing sedation with dexmedetomidine after spinal anesthesia.

Patients undergoing sedation with dexmedetomidine after spinal anesthesia are randomly assigned to binaural group, audio group, and control group. After spinal anesthesia, SedLine continuous monitoring is started. Real-time binaural sound applied music is played to the binaural group, normal music is played to the audio group, and headphones with no sound are applied to the control group. Observer's Assessment of Alertness/Sedation Scale (OAAS) and Patient State Index (PSi) are checked every minute after loading of dexmedetomidine at the rate of 1 μg/kg for 10 minutes (6 μg/kg/hr). Loading is stopped when the OAAS score is 3 or less. Then, dexmedetomidine is continuously infused at a rate of 0.6 μg/kg/hr, and OAAS is evaluated every 30 minutes. The infusion rate is lowered (-0.1 μg/kg/hr) if OAAS is lower than 3, and increased (+0.1 μg/kg/hr) if OAAS is higher than 3. The continuous infusion rate should not exceed 1 μg/kg/hr. The total dexmedetomidine dose corrected by the patient's predicted body weight and infusion time (μg/kg/hr) was compared between groups. In addition, the loading dose (μg/kg) and continuous infusion dose (μg/kg/hr), additional sedative use, blood pressure, heart rate, ECG changes, respiratory depression, and oxygen saturation were observed. The patient's satisfaction is evaluated after the surgery.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients undergoing sedation with dexmedetomidine during spinal anesthesia for surgery with an estimated time of 90 minutes or longer

Exclusion Criteria:

* ASA physical status classification 3-4
* Patients with hearing loss or using hearing aids
* Patients who received narcotic analgesics or sedative drugs within 1 week
* Patients with alcohol dependence or drug dependence
* Patients with drug hypersensitivity to dexmedetomidine
* Patients with arrhythmia, cardiovascular disease, decreased cardiac function and decreased cardiac output
* Patients who are judged to be difficult to use sedative drugs due to severe respiratory disease
* Patients with liver failure
* Patients with kidney failure or on dialysis
* Patients judged to be unsuitable for the clinical trial by the researchers
* Patients whose actual operation time is less than 30 minutes
A Randomized Study on Comparing the Efficacy of Foley Catheter and Extraamniotic Saline Infusion for Labor Induction

Our purpose was to compare the efficacy and safety of Foley catheter with oxytocin and extraamniotic saline infusion with oxytocin for induction of labor requiring cervical ripening.

Induction of labor is indicated when the benefit to either the mother or fetus outweighs that of continuing the pregnancy. Labor induction in the presence of an unripened cervix is associated with prolonged labor, chorioamnionitis, and cesarean delivery. Numerous mechanical and pharmacological methods have been used for cervical ripening. There are limited numbers of rigorous studies comparing the efficacy of the various methods. One of the most common mechanical methods for cervical ripening is placement of a Foley catheter with a 30 cc balloon inside the cervix, with or without the use of oxytocin. The Foley balloon will disrupt the amniotic membrane surface and cause the release of prostaglandin, a natural chemical from the cervix, to facilitate the ripening process. Oxytocin will be used concurrently as the induction agent. Recently, a modification of this method, extraamniotic saline infusion (EASI) has become more popular. The EASI method involves similar procedure including the placement of Foley catheter inside the cervix; in addition, saline solution will be infused through the catheter. This additional step is thought to further facilitate the disruption of amniotic membrane surface. Both methods are safe and become the standard treatment for cervical ripening. However, there are no published trials so far comparing the two methods. The objective of this study is to compare the efficacy and safety of Foley catheter with oxytocin and EASI with oxytocin for induction of labor requiring cervical ripening. The study is designed to be a single masked randomized trial.

Eligibility Criteria:
Inclusion Criteria:

* singleton gestation
* cephalic vertex presentation
* intact membrane
* gestational age between 30 and 42 weeks
* Bishop score less than or equal to 5

Exclusion Criteria:

* suspected chorioamnionitis
* placenta previa
* low lying placenta
* unexplained vaginal bleeding
* intrauterine fetal demise
* HIV
* any contraindication to vaginal delivery
Real-World Evaluation of Eko Murmur Analysis Software in a Point of Care Setting

The purpose of this research is to evaluate the impact of Eko AI plus EMAS (Eko Murmur Analysis Software) on a clinician's referral decision in a real-world primary care setting. There is an additional objective of understanding patient outcomes when patients are referred for cardiology follow-up and/or echocardiogram.

Eko has developed a platform to aid in screening for cardiac conditions using a digital stethoscope and machine-learning algorithms to detect the presence or absence of heart conditions such as heart murmurs and atrial fibrillation. In June 2022, the US Food and Drug Administration (FDA) granted Eko a 510(k) clearance for the marketing of "Eko Murmur Analysis Software" (EMAS), a set of machine learning algorithms that are able to screen signal quality and identify fundamental heart sounds, distinguish structural murmurs from absent or innocent murmurs, and provide a structural murmur's timing in the cardiac cycle.

This study sets out to evaluate the impact of EMAS on a clinician's referral decision in a real-world primary care setting, with the additional objective of understanding patient outcomes when patients are referred for cardiology follow-up and/or echocardiogram. Providers will receive access to the EMAS screening tool, called the SENSORA™ Disease Detection Platform, which features the FDA cleared 3M™ Littmann® CORE stethoscope paired with the FDA cleared SENSORA™ enterprise application and EMAS AI running on an iPad, which is mounted on a Tryten stand. SENSORA™ will be used by medical assistants or equivalent as part of the initial patient intake process (e.g., during vitals acquisition).

EMAS influence on individual providers will be assessed by reviewing each provider's number of referrals to cardiology and number of echocardiogram orders for the 6 months preceding study start. These values will be compared to cardiac referral and order rates at the end of the study. Patient outcomes data (e.g., cardiology appointment notes, echocardiogram findings, follow up visits scheduled) will be pulled 6 months after the patient is seen by their primary care provider. Secondary objectives include the continued assessment of algorithm performance on a point-of-care population.

Eligibility Criteria:
Inclusion Criteria:

* Patient verbally consents to participation
* Patient is willing to have heart sounds recorded with an electronic stethoscope
* Patient is age 50 years or older

Exclusion Criteria:

* Patient is unwilling or unable to give verbal informed consent
* Patients experiencing a known or suspected acute cardiac event
* Patient is under the age of 50 years old
Booster of the "More Time for Patients" Program

The goal of this clinical trial is to determine if reactivating a hospital program called "Plus de temps au service des patients" (PTP) can improve the quality of pain management for patients and increase job satisfaction among healthcare professionals. The main questions this study aims to answer are:

* Does reactivating PTP improve the quality of pain management?
* Does reactivating PTP increase healthcare professionals' job satisfaction? In this study, researchers will compare the effects of reactivating the program immediately to reactivating it after a 3-month delay.

Participants in the trial are healthcare professionals who will:

* Select 2 or 3 elements of the program they believe would be most beneficial to reactivate in their hospital units.
* Implement the selected elements for 3 months.
* Complete job satisfaction and burnout questionnaires before and after the study.


Eligibility Criteria:
Inclusion criteria for the units:

* Implementation of PTP finished at least 6 months previously
* Agreement to the study from both medical head of service and head of unit (IRES)

Inclusion criteria for healthcare professionals:

* Healthcare professionals \>18 yo.
* Healthcare professionals working in a HUG service of medicine or surgery.
* Healthcare professionals include Physicians, Nurses, Assistant Nurses, Pharmacists, Physiotherapists and other physical therapists.
* Provided general informed consent.

Inclusion criteria for patients

* Patients hospitalised in one of the boosted units.
* Cognitive ability to provide satisfaction assessment.
Outcome of Balloon Pulmonary Valvuloplasty in Patients With Congenital Pulmonary Stenosis in Terms of Reverse Right Ventricular Remodelling and Functional Exercise Capacity

A prospective of 30 patients with symptomatic severe congenital valvular pulmonary stenosis who are indicated for percutaneous balloon pulmonary valvuloplasty . the aim is to

1. - evaluate electrical and mechanical remodeling of RV 6 months following balloon dilation
2. - evaluate Functional capacity using 6MWT and SaO2 before and 6 months following BPV

Valvular pulmonary stenosis (PS), defined as an obstruction of blood flow at the level of the pulmonary valve, is a form of congenital heart disease, described in 0.6-0.8 out of 1000 live births.

The main physiologic effect of valvular pulmonary stenosis (PS) is an increase in Right ventricular pressure proportional to the severity of obstruction. This elevation of RV pressure is accompanied by an increase in muscle mass where hyperplasia of the muscle cells with a concomitant increase in the number of capillaries occurs. In contrast, the adult myocardium responds with hypertrophy of the existing fibers, with no change in the capillary network. Percutaneous balloon pulmonary valvuloplasty (PBPV) is the procedure of choice for uncomplicated severe or symptomatic pulmonary stenosis. the aim is to

1. - evaluate electrical and mechanical remodeling of RV 6 months following balloon dilation
2. - evaluate Functional capacity using 6MWT and SaO2 before and 6 months following BPV

Eligibility Criteria:
Inclusion Criteria:

* 1-Adult population with an age more than or equal to 16 years of age at time of procedure 2-Severe valvular Pulmonary stenosis defined as a PG max more than or equal to 64 mmHg measured by 2d echo before Procedure

Exclusion Criteria:

1. Patients with isolated supra-valvular and sub valvular pulmonary stenosis
2. Patients with peripheral pulmonary stenosis.
3. Patients with pulmonary stenosis if part of another congenital heart disease .
4. Patients with organically diseased Tricuspid valve
5. Patients with any significant shunt lesion which result in dilation in RV such as atrial septal defect.
6. Patients with right ventricular dysfunction due to arrhythmogenic right ventricular dysplasia (ARVD) or non compaction
Collection of Microbiome Samples of Healthy Western Donors for Fundamental and Functional Microbiome Research

Large numbers of micro-organisms (especially bacteria) live in and on human bodies and have a very important function for the health. These microorganisms are called 'the microbiota'. They aid in the digestion of food, ensure the production of certain vitamins, and are very important for the development and regulation of the immune system. In many diseases (including Crohn's disease, arthritis, obesity, diabetes and cancer), a disruption of microbial composition is observed. There are indications that a disruption of the microbiome can contribute to the development of inflammatory diseases and cancer, but the underlying processes are not sufficiently understood. To understand the mechanisms underlying these disease processes, fundamental research is conducted at Ghent University. Stool, skin, oral and vaginal samples from various origins are examined, e.g. from people from indigenous tribes with a traditional lifestyle. It is important that these samples can be compared with microbiome samples from healthy Western (West-European) controls. In this study, the investigators want to build up a collection of samples from healthy donors between the ages of 2 and 70, with the exception of vaginal samples collected from women between the ages of 18 and 45. The samples will form the basis for further fundamental and functional research into microbiota-host interactions at Ghent University.


Eligibility Criteria:
Inclusion Criteria:

* Healthy
* Age between 2 and 70 years old
* Dutch speaking
* West-European origin

Exclusion Criteria:

* Diagnosis of chronic disease (such as osteoarthritis, rheumatoid arthritis, diabetes, Crohn's disease, inflammatory bowel disease (IBD), asthma, COPD, etc.)
* Antibiotics taken within 3 months before sampling
Use of Laser Speckle to Study Cutaneous Blood Flow at Exercise in Healthy Subjects

We aim to test the hypothesis that Laser speckle contrast imaging allows for the measurement of cutaneous blood flow during exercise.

Ischemia and post occlusive reactive hyperhemia in the skin is tested in healthy normal subjects at rest and during cycle exercise.

Eligibility Criteria:
Inclusion Criteria:

* Healthy volunteers
* Affiliation to the French health system

Exclusion Criteria:

* Any disease or chronic treatment
ADenoVirus Initiative Study in Epidemiology in UK

The objectives of this study is to assess the characteristics and frequency of adenovirus conjunctivitis in a population of male and female patients from one year of age who present signs and symptoms of acute conjunctivitis.

Epidemiological, prospective, open, multicentric trial in patients suffering from acute conjunctivitis who will undergo a rapid diagnostic test for adenoviral conjunctivitis at the time of their visit to the ophthalmologist office, at the emergency room or during hospitalization. This epidemiological study will include approximately 500 patients in the United Kingdom. The planned duration of the study is one year from the first patient visit to the last patient visit.

Eligibility Criteria:
Inclusion Criteria:

* Male or Female patients of at least one year of age presenting acute (for less than 7 days) conjunctivitis signs and symptoms.
* Patient or / and legal representative (if patient below 18 years of age) must be able to provide oral consent for the collection and treatment of the questionnaire data.
* No history of hypersensitivity to corn starch, talcum powder or Dacron (sampling fleece components).

Exclusion Criteria:

* Current use or having received (within the last 7 days) local antiviral therapies such as povidone iodine or ganciclovir, or topical steroids or immunomodulators such as cyclosporine which may interfere with the test result.
* Previous enrolment in the present study.
* Any direct involvement with the study conduct at site or any family link with study site staff.
Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma

The outlook for patients with haematological malignancies remains challenging. It has been shown in some early cancer studies that a particular drug called Zn-DDC otherwise known as Imuthiol is highly toxic to cancer stem cells. Imuthiol has been intravenously used in clinical trials with an excellent safety record. Recent novel therapy and immunotherapy in haematological malignancies have improved outcome and survival but come with an increasing cost burden. Imuthiol could be an ideal affordable drug to study on it's own as well as in combination with other drugs in myeloma and other haematological malignancies. This may lead to potential combination therapies which will be very effective as well as affordable in the future. There is the need to look to see if this drug, Imuthiol and along with complementary drugs lenalidomide (Revlimid) and pomalidomide (Pomalyst) can help in haematological malignancy treatment. In order to do this there is the need to see how the cancer cells respond to the drugs in the laboratory before being able to trial the drug (or combination of drugs) out for treatment. The success of this study may lead to quick translation of Imuthiol into haematological malignancy treatment.

Up to 60 myeloma bone marrow samples from Myeloma patients and 10 bone marrow samples from other haematological malignancy samples (Acute leukaemia's) at Diagnosis and Relapse will be tested.

Patients attending haematology clinics at New Cross Hospital will be reviewed for eligibility of the study by the clinician and if they meet the recruitment criteria, they will be approached to participate at clinic.

After informed consent, participants will be asked to donate an additional 2-3ml sample of bone marrow in a single aliquot for the purpose of this study whilst undergoing a bone marrow aspirate as part of their routine clinical care at diagnosis and relapse.The single aliquot will be sent to the University of Wolverhampton for analysis.

Specific clincial data will be collected at the time of diagnosis and relapse:

* Diagnosis
* Date diagnosed
* Disease stage
* Relapse status
* Age
* Sex
* Previous treatments
* Date of marrow sample
* Marrow trephine
* Marrow liquid The clinical data set will remain at The Royal Wolverhampton NHS Trust whilst analysis of the samples takes place. Once the samples have been analysed, the clinical data will then be released to determine relapsed or refractory disease and correlation with the in vitro data.

Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with haematological malignancy - either myeloma or acute leukaemia
* Patients must be 18 years or over
* Patients must be willing and able to give informed consent

Exclusion Criteria:

* Pregnant patients will not be entered
Ultrasound Assessment of Residual Gastric Content in Critically Ill Patients

This prospective observational study aims to assess whether ultrasound assessment of gastric content may be useful for the monitoring of the gastric residual content in critically ill patients


Eligibility Criteria:
Inclusion Criteria:

* Critically ill patients under mechanical ventilation and enteral feeding through a gastric tube since \>48 h

Exclusion Criteria:

* Digestive hemorrhage Contra-indication to prokinetic drugs Enteral feeding through jejunostomy or gastrostomy Pregnancy
Pneumatic Retinopexy for Severe Bullous Retinal Detachment

To compare the efficacy and safety outcomes of scleral buckling (SB) and drainage-injection-pneumoretinopexy (DIP), a modified pneumatic retinopexy technique, in which, before injecting the gas, the drainage of the subretinal fluid is performed with a simultaneous injection of balanced salt solution (BSS) in the vitreous chamber, for the treatment of severe superior bullous rhegmatogenous retinal detachment (SBRD).


Eligibility Criteria:
Inclusion Criteria:

* provision of written informed consent;
* phakic patients aged \< 60 years with no or minimal media opacity;
* single or multiple retinal breaks (within 1 clock hour) between 8 to 4 o'clock hours;
* patients' capability to maintain suggested head positioning for 5 days after the procedure.

Exclusion Criteria:

* retinal detachment with poor subretinal fluid (absence of severe SBRD);
* holes, lattice degeneration or traction within the inferior 4 clock hours;
* posterior retinal break, situated behind the equator, not suitable for cryotherapy;
* any sign of PVR or severe glaucoma;
* myopia above 10 diopters.